Scientists create atlas of rare lymphoma to unlock new treatment clues
NCT ID NCT07376330
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will analyze tissue samples from 400 people with MALT lymphoma, a slow-growing cancer. Researchers aim to build a comprehensive molecular and cellular map of the disease across different body sites. The goal is to identify tumor subtypes and biomarkers that could improve diagnosis, prognosis, and therapy in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could identify new biomarkers and subtypes of MALT lymphoma, potentially pointing toward more personalized diagnosis and treatment approaches.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test any therapy, and the findings may not immediately lead to new treatments or change clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS Ospedale San Raffaele
Milan, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.